Discover
PPCB
Propanc Biopharma, Inc.
0.49
2 x 0.36
2 x 0.65
bid
ask
+
0.01
3.12%
2 @ 07:55 PM
0.46 -0.02 (4.47%)
| Ytd | -96.38% | |
| 1y | -98.97% |
0.46
day range
0.50
0.47
52 week range
47.00
| Open | 0.50 | Prev Close | 0.47 | Low | 0.46 | High | 0.50 | Mkt Cap | 4.77M |
| Vol | 197.01K | Avg Vol | 1.79M | EPS | -17.96 | P/E | N/A | Forward P/E | N/A |
| Beta | 3.53 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 0.94 | 200-d Avg | 3.40 | 1yr Est | 0.00 |
| Income Statement | |||
| Operating Expenses | 3.46M | ||
| Research and Development Expense | 375.66K | ||
| Selling, General and Administrative Expense | 3.08M | ||
| Operating Income | -3.46M | ||
| Interest Expense | 27.67K | ||
| Net Income | -4.57M | ||
| Net Income Common Stock | -4.57M | ||
| Net Income Common Stock (USD) | -4.57M | ||
| Consolidated Income | -4.57M | ||
| Earnings per Basic Share | 6.20 | ||
| Earnings per Basic Share (USD) | 6.20 | ||
| Earnings per Diluted Share | 6.20 | ||
| Earning Before Interest & Taxes (EBIT) | -4.55M | ||
| Earning Before Interest & Taxes (USD) | -4.55M | ||
| Weighted Average Shares | 1.12M | ||
| Weighted Average Shares Diluted | 1.12M | ||
| Balance Sheet | |||
| Cash and Equivalents | 832.01K | ||
| Cash and Equivalents (USD) | 832.01K | ||
| Current Assets | 8.54M | ||
| Property, Plant & Equipment Net | 44.71K | ||
| Total Assets | 12.78M | ||
| Debt Current | 485.30K | ||
| Total Debt | 509.12K | ||
| Current Liabilities | 3.35M | ||
| Debt Non-Current | 23.82K | ||
| Total Liabilities | 3.38M | ||
| Accumulated Retained Earnings (Deficit) | -144.48M | ||
| Accumulated Other Comprehensive Income | 1.18M | ||
| Shareholders Equity | 9.40M | ||
| Shareholders Equity (USD) | 9.40M | ||
| Assets Non-Current | 4.24M | ||
| Total Debt (USD) | 509.12K | ||
| Liabilities Non-Current | 23.82K | ||
| Trade and Non-Trade Payables | 1.13M | ||
| Tax Assets | 13.69K | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 6.38K | ||
| Net Cash Flow from Financing | 1.98M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 388.30K | ||
| Capital Expenditure | -21.00 | ||
| Issuance (Repayment) of Debt Securities | -16.19K | ||
| Net Cash Flow from Investing | -21.00 | ||
| Net Cash Flow from Operations | -1.60M | ||
| Effect of Exchange Rate Changes on Cash | 6.49K | ||
| Share Based Compensation | 5.48M | ||